Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.36 |
| ▸ | ANPEP | P15144 | 3/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22654848 | 0.86 | FKBP1A (0.37) | FKBP1AMAPT | |
| SCHEMBL27158695 | 0.86 | FKBP1A (0.34) | FKBP1AMAPTNFKB1NFKB2RELA | |
| SCHEMBL2534501 | 0.84 | NR1D1 (0.32) | FKBP1ANR1D1 | |
| SCHEMBL27158567 | 0.82 | FKBP1A (0.32) | FKBP1ANR1D1 | |
| SCHEMBL201253 | 0.78 | MMP2 (0.57) | MMP2ANPEPDPP4DPP8DPP9 | |
| SCHEMBL15083833 | 0.78 | MMP2 (0.57) | MMP2ANPEPDPP4DPP8DPP9 | |
| SCHEMBL27159103 | 0.77 | FKBP1A (0.33) | FKBP1A | |
| SCHEMBL9273462 | 0.75 | PTPN1 (0.41) | MMP2ANPEPFKBP1ANR1D1MAPT | |
| SCHEMBL8273056 | 0.75 | PTPN1 (0.41) | MMP2ANPEPFKBP1ANR1D1MAPT | |
| SCHEMBL8404085 | 0.75 | NR1D1 (0.42) | MMP2ANPEPFKBP1ANR1D1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4332105-A1 | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-8653070-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | MMP2 2732/4885ANPEP 755/4885FKBP1A 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.